Alcohol Medication Options: FDA Approvals and Off-Label Uses

Medications for alcohol use disorder exist and work, yet most people who could benefit from them never receive a prescription. Three drugs carry FDA approval specifically for helping people reduce or stop drinking, several more are used off-label with promising evidence, and a new generation of candidates is in clinical trials. At the same time, alcohol interacts dangerously with a wide range of common medications, from painkillers to antibiotics, in ways that many people underestimate. Both sides of the “alcohol medication” coin deserve a closer look.

The Three FDA-Approved Medications

Only three medications currently have FDA approval for treating alcohol use disorder: disulfiram, naltrexone, and acamprosate. Each works through a completely different mechanism, which means they suit different people and different treatment goals.

Disulfiram, marketed as Antabuse, is the oldest of the three. It blocks the enzyme that breaks down acetaldehyde, a toxic byproduct your body normally clears quickly after drinking. If you drink while taking disulfiram, acetaldehyde builds up and produces flushing, headache, and nausea. A systematic review of randomized trials found that disulfiram roughly doubled the likelihood of staying abstinent compared to placebo, and dramatically reduced heavy drinking, though it also caused substantially more people to drop out of treatment.¹ The logic is straightforward deterrence: knowing that a drink will make you violently ill keeps you from reaching for one. It works best for people who are highly motivated and have someone helping ensure they take the pill daily.

Naltrexone takes a different approach entirely. Rather than punishing you for drinking, it blunts the reward. Naltrexone is a competitive antagonist at mu-opioid receptors, which means it blocks the brain’s own opioid system from delivering the pleasurable buzz that alcohol normally triggers.² If you drink on naltrexone, you still feel some of alcohol’s sedating effects, but the “this is great, have another” signal is muted. That makes it easier to stop at one or two drinks instead of sliding into a binge.

Acamprosate works on yet another system. When someone drinks heavily over a long period, the brain’s excitatory signaling becomes ramped up to compensate for alcohol’s depressant effects. Remove the alcohol suddenly, and the brain is left in a hyperexcitable state that produces anxiety, restlessness, and intense cravings. Acamprosate calms this by modulating glutamate signaling, dampening the overactive excitatory tone that makes early sobriety feel so uncomfortable.³ Research suggests it acts as an antagonist at a specific glutamate receptor subtype, which helps explain why it can reduce the surge of brain excitability that follows alcohol withdrawal.⁴

Matching the Medication to the Goal

Because these drugs target different parts of the problem, they tend to shine under different circumstances. Meta-analyses comparing the two most commonly prescribed options, naltrexone and acamprosate, have found a consistent pattern: acamprosate is better at helping people who have already stopped drinking stay abstinent, while naltrexone is better at reducing heavy drinking and cravings in people who are still drinking or at risk of relapse.⁵ Another way researchers have framed it: acamprosate is more effective at preventing the first drink, while naltrexone is better at preventing that first drink from spiraling into full relapse.⁶

This distinction matters for treatment planning. Someone who has completed detox, is committed to total abstinence, and wants help staying the course may benefit more from acamprosate. Someone who is still drinking, not ready for full abstinence but wants to cut back and avoid binges, may get more from naltrexone. Disulfiram is typically reserved for people who are already abstinent and want a strong external deterrent, and it requires someone who will reliably take a daily pill knowing it will make drinking miserable.

Off-Label Options

Several medications developed for other conditions have shown enough promise in alcohol use disorder to earn a following among addiction specialists, even without formal FDA approval for that purpose.

Topiramate, an anticonvulsant originally used for epilepsy and migraine, appears to dampen the dopamine reward pathway through two routes: it enhances the brain’s inhibitory signaling and blocks certain excitatory glutamate receptors.⁷ The net effect, in controlled trials, has been reduced drinking. Its side-effect profile, including cognitive dulling and tingling in the extremities, limits its appeal for some patients, but for those who tolerate it, it represents a useful alternative.

Baclofen, a muscle relaxant that acts on the brain’s inhibitory GABA-B receptors, has drawn particular interest for a specific population: people with alcohol use disorder who also have liver cirrhosis. Most medications for alcohol dependence are processed by the liver, which makes prescribing them tricky in patients whose livers are already compromised. Baclofen is primarily cleared by the kidneys, which gives it a safety advantage in this group. A randomized, double-blind trial found that about 71% of patients with liver cirrhosis who received baclofen achieved and maintained abstinence, compared to 29% on placebo.⁸ A decade of follow-up research has continued to support baclofen’s effectiveness and safety in this population.⁹

Emerging Therapies That Are Generating Buzz

Two newer candidates have attracted considerable media attention. Semaglutide, the active ingredient in the widely prescribed weight-loss and diabetes drugs, showed intriguing effects in a recent randomized trial. Participants receiving low-dose semaglutide consumed less alcohol per drinking day, reported lower weekly cravings, and showed greater reductions in heavy drinking over time compared to placebo, with medium-to-large effect sizes on laboratory measures of alcohol consumption.¹⁰ The drug did not change the total number of drinking days, which suggests it may work by making people drink less when they do drink rather than by stopping them from drinking altogether. Researchers suspect semaglutide dampens the dopamine reward response to alcohol, much as it appears to reduce the reward from food. These are early results from a single trial, and larger studies are underway.

Psilocybin-assisted therapy is also under investigation. Several trials are testing whether guided psychedelic sessions, combined with psychotherapy, can produce lasting reductions in heavy drinking. One ongoing trial is randomizing 90 participants with alcohol use disorder to psilocybin or placebo, with heavy drinking days as the primary outcome.¹¹ Early-phase results from other research groups have been encouraging, but this remains experimental, and the field is far from settled on dosing, session structure, or which patients benefit most.

Why So Few People Get Treated

Despite having three approved medications with proven efficacy, the treatment gap is enormous. The approved drugs are widely underprescribed, and primary care providers show marked variability in how often they offer them.¹² A qualitative study across five VA primary care clinics identified several stubborn barriers: many providers lacked knowledge about or experience with the medications, some believed that medication could never substitute for specialty addiction treatment, and alcohol-related stigma colored clinical judgment.¹³

Adherence is another bottleneck. Oral naltrexone requires taking a pill every day, and many people with alcohol dependence struggle with daily medication routines. This led to the development of a once-monthly injectable form of naltrexone, which removes the daily decision from the equation. The injectable formulation has been linked to better drinking outcomes, especially among people who were already abstinent when they started treatment.¹⁴ Getting a shot once a month is simply easier to sustain than remembering a pill every morning, and it eliminates the temptation to skip a dose before a planned drinking occasion.

Genetics and Why the Same Drug Works Differently in Different People

One of the more frustrating aspects of treating alcohol use disorder is the unpredictability. Naltrexone works well for some people and does almost nothing for others, which has pushed researchers toward pharmacogenomics, the idea that genetic differences can predict who responds to a given drug.

The most studied genetic marker is a variant in the OPRM1 gene, which codes for the mu-opioid receptor that naltrexone targets. A 2012 meta-analysis found that naltrexone-treated patients carrying the G allele of this variant had about half the relapse rate of those who carried only the more common A allele.¹⁵ However, a more recent study of extended-release naltrexone found the opposite pattern: the A/A genotype was associated with longer abstinence, lower relapse rates, and higher treatment completion, while the G allele increased relapse risk.¹⁶

These conflicting findings are a good illustration of where the science stands: promising but not yet ready for routine clinical use. Differences in study design, the formulation of naltrexone being tested, patient motivation, and the specific outcomes measured can all influence which genetic variant appears favorable. Genetic testing to guide medication choice remains more of a research tool than a standard clinical practice, though it is inching closer.

How Alcohol Dependence Rewires the Brain

Understanding why these medications are needed at all requires appreciating what chronic heavy drinking does to brain chemistry. Alcohol’s initial effects hit several neurotransmitter systems at once, boosting inhibitory signaling while dampening excitatory activity. Over time, the brain pushes back, compensating by ramping up excitatory pathways and dialing down inhibitory ones. The result is a brain that has adapted to the presence of alcohol and feels profoundly abnormal without it.¹⁷

One especially important piece of this puzzle involves the brain’s stress system. Alcohol dependence recruits a stress hormone called corticotropin-releasing factor (CRF) within the amygdala. In people with a history of dependence, this system becomes persistently overactive, creating a chronic state of low-grade anxiety and emotional distress that drives the urge to drink for relief rather than pleasure.¹⁸ This shift from drinking for reward to drinking to escape negative feelings is a hallmark of severe dependence, and it helps explain why willpower alone so often falls short. The person is not merely choosing to drink; their brain is generating an internal emergency that alcohol temporarily silences.

Alcohol and Other Medications You May Already Take

The other meaning of “alcohol medication” is the interaction between drinking and drugs prescribed for unrelated conditions. This is a much broader public health concern, and the list of problematic combinations is long. Numerous classes of prescription drugs can interact with alcohol, including antidepressants, antihistamines, benzodiazepines, muscle relaxants, opioids, nonsteroidal anti-inflammatory drugs, and blood thinners like warfarin.¹⁹ Most of these interactions happen in the liver, where alcohol and many medications compete for the same metabolizing enzymes.

The most dangerous interactions involve drugs that, like alcohol, depress the central nervous system. Combining alcohol with opioid painkillers or benzodiazepines (drugs like diazepam, lorazepam, or alprazolam) does not merely add their sedating effects together; it can multiply them. Patients using opioids alongside benzodiazepines and alcohol face a sharply elevated risk of fatal overdose.²⁰ Alcohol enhances the depressant effects of sedatives, certain antidepressants, antipsychotics, and anticholinergic agents on performance and coordination, even at moderate doses.²¹

Acetaminophen (Tylenol) and alcohol represent another common and underappreciated combination. Chronic alcohol use changes the way the liver processes acetaminophen, increasing the amount that gets converted to a toxic byproduct. This increased risk of liver injury persists even when someone takes acetaminophen shortly after their body has cleared the alcohol from a prior session.²² The person does not need to be drinking and taking Tylenol at the same moment; a regular heavy drinker who reaches for acetaminophen the morning after is still at elevated risk.

Antibiotics and the Myth That Got It Half Right

The widespread belief that you must never drink on antibiotics is partly myth and partly real. For most common antibiotics, including amoxicillin and azithromycin, alcohol does not create a dangerous chemical reaction. It may slow your recovery by disrupting sleep and straining your immune system, but it does not produce a specific pharmacological interaction.

Metronidazole is the exception that gave rise to the rule. This antibiotic, commonly prescribed for dental infections and certain gut parasites, can produce a disulfiram-like reaction when combined with alcohol: flushing, nausea, vomiting, and rapid heartbeat. The mechanism resembles what disulfiram does deliberately, though the reaction occurs with uncertain frequency and varies in severity.²³ What often gets missed is that the alcohol does not have to come from a drink. Liquid medications that contain alcohol as a solvent can also trigger the reaction, which has caught patients and clinicians off guard when the alcohol source was a cough syrup or mouthwash rather than a cocktail.²⁴

Tracking Whether Treatment Is Working

One persistent challenge in alcohol treatment research and clinical practice is that people underreport how much they drink. Self-report questionnaires are the most common tool, but they are unreliable for obvious reasons: memory is imperfect, stigma discourages honesty, and heavy drinkers may not accurately gauge what counts as a “standard drink.” This has driven interest in objective biomarkers that can verify whether someone is actually drinking less.

Phosphatidylethanol, known as PEth, is a phospholipid that forms in red blood cell membranes only when ethanol is present. It accumulates with repeated drinking and clears slowly enough to capture a pattern over weeks rather than hours, giving clinicians a wider window than a breathalyzer or standard blood-alcohol test. Research comparing PEth levels to self-reported drinking in clinical trials has confirmed that the biomarker adds meaningful information beyond what patients report on their own.²⁵ More recent work supports PEth as a practical measure of heavy drinking days in clinical settings, offering a way to objectively gauge whether a medication is working as intended.²⁶

PEth testing is not yet standard in most primary care offices, but its adoption is growing in research settings and specialized addiction clinics. For patients, knowing that a blood test can independently verify their progress can serve as both a motivator and a reality check. For clinicians, it provides something that has long been missing from alcohol treatment: a relatively straightforward lab value that says whether the intervention is moving the needle.